Back to top
more

Recro Pharma, Inc. (REPH)

(Delayed Data from NSDQ)

$9.00 USD

9.00
239,789

0.00 (0.00%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.99 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

by Zacks Equity Research

Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

5 Domestic Stocks to Gain From Thaw in Trade Talks

by Zacks Equity Research

The United States and China's outstanding disagreements on a few key issues could delay a favorable deal.

Recro Pharma (REPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Recro Pharma (REPH) delivered earnings and revenue surprises of 4.48% and 9.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

FDA Sets Action Date for Recro's Pain Management Candidate

by Zacks Equity Research

The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.

    Recro Pharma (REPH) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Recro Pharma (REPH) delivered earnings and revenue surprises of 54.07% and 29.35%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars

      by Zacks Equity Research

      Adamas Pharmaceuticals' (ADMS) Gocovri was approved by the FDA for treating dyskinesia in patients with Parkinson's disease. This led to an upside in shares.

        Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View

        by Zacks Equity Research

        Lannett (LCI) reported in-line Q4 earnings and sales. The FDA approved multiple pending ANDAs during the quarter. Also, the company provided strong outlook for 2018.

          Company News for November 29, 2016

          by Zacks Equity Research

          Companies in the News are: CTSH,PZRX,REPH,SFUN